Onkologie. 2016:10(3):114-119 | DOI: 10.36290/xon.2016.025

Myelodysplastic syndromes in 2016

Jaroslav Čermák
Ústav hematologie a krevní transfuze, Praha

Myelodysplastic syndromes (MDS) represent a group of clonal disorders hematopoiesis of a great current scientific interest. Identification

of new prognostic factors should more precisely define a subgroup of high risk patients within a group of patiens with

early disease with generally good prognosis. These patients should be indicated for intensive treatment including stem cell transplantation

early after diagnosis. New treatment approaches to early MDS include correction of ineffective eythropoiesis, in patiens

with advanced disease, clinical research is focused on targeted treatment that might decrease a risk of relapse after transplantation.

Keywords: myelodysplastic syndromes, classification, diagnosis, prognosis, treatment

Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čermák J. Myelodysplastic syndromes in 2016. Onkologie. 2016;10(3):114-119. doi: 10.36290/xon.2016.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bennett J, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199. Go to original source... Go to PubMed...
    2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November, 1997. J Clin Oncol 1999; 17: 3835-3839. Go to original source... Go to PubMed...
    3. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms overview. S. 88-93 in: WHO classification of tumours of Haematopoietic and Lymphoid Tissues, ed. By S.H. Swerdlow et al, IARC, Lyon, 2008.
    4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88. Go to original source...
    5. Schanz J, Tuchler H, Sole F, et al. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol. 2012; 30: 820-829. Go to original source... Go to PubMed...
    6. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System(IPSS-R) for myelodysplastic syndromes. Blood. 2012; 120: 2454-2465. Go to original source... Go to PubMed...
    7. Bejar R, Stevenson K, Bennett A, et al. Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic SyndromesJ Clin Oncol 2012; 30: 3376-3382. Go to original source... Go to PubMed...
    8. Malcovati L, Hellström-Lindberg E, Bowen D, Ad?s L, Cermak J, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943-2964. Go to original source... Go to PubMed...
    9. Van de Loosdrecht AA, Ireland R, Kern W, et al. Rationale for the clinical application of flow cytometry in patients withmyelodysplastic syndromes: position paper of an International Consortium and the European Leukemia Net Working Group. Leukemia & Lymphoma 2013; 54: 472-475. Go to original source... Go to PubMed...
    10. Bejar R, Papaemmanuil E, Haferlach T, et al. Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood 2015; 126: 907 /abstr/. Go to original source...
    11. Papaemmanuil E, Gerstung M, Malcovati L, et al. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22): 3616-3627. Go to original source... Go to PubMed...
    12. Gattermann N, Jarisch A, Schlag R, et al. Deferasirox treatment of iron-overloaded chelation-naive and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. Eur J Haematol. 2012; 88: 260-268. Go to original source... Go to PubMed...
    13. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67-71. Go to original source... Go to PubMed...
    14. Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol. 2011; 29: 303-309. Go to original source... Go to PubMed...
    15. Jonášová A, Neuwirtová R, Čermák J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 314-309. Go to original source...
    16. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465. Go to original source... Go to PubMed...
    17. Giagounidis A, Platzbecker U, Germing U, et al. Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. Blood 2015; 126: 92 /abstr/. Go to original source...
    18. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004.
    19. Fenaux P, Mufti G, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk MDS: a randomized, open-label, phase III study. Lancet Oncology 2009; 10: 223-232. Go to original source... Go to PubMed...
    20. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneichematopoietic stem cell transplantation using HLA-identical sibling donors inmyelodysplastic syndromes. Blood 2006; 108: 836-846. Go to original source... Go to PubMed...
    21. Damaj G, Duhamel A, Robin M, et al. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-FrancophoneDes Myelodysplasies. J Clin Oncol 2012; 30: 4533-4540. Go to original source... Go to PubMed...
    22. Zwierzina H, Suciu S, Loeffler-Ragg J, et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk ofdeveloping acute leukemia: final results of a randomized phase III study (06903)of the EORTC Leukemia Cooperative Group. Leukemia. 2005; 19: 1929-1933. Go to original source... Go to PubMed...
    23. Koreth J, Pidala J, Waleska S, et al. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. J Clin Oncol 2013; 31: 2662-2670. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.